Picture Berlin Partner Life Sciences Report 2019/2020 Brandenburg 650x80px
Organisation › Details

Oxford Immunotec (Group)

Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions. The Company’s first product is the T-SPOT®.TB test, which is used to test for tuberculosis infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The Company’s second product line is a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and Immunetics. Also obtained through the acquisitions is the Company’s third product line focused on screening for Babesia in donated blood, for which the Company is currently seeking FDA licensure. The T-SPOT.CMV test and the T-SPOT.PRT test are pipeline products as part of the Company’s fourth intended product line focused on the transplantation market. In addition to these four product lines, the Company has additional active development programs in other immune-regulated conditions. The Company is headquartered near Oxford, U.K. and in Marlborough, Mass. *


Period Start 2002-11-01 splitoff
  Today Oxford Immunotec Ltd.
  Predecessor University of Oxford
Products Industry diagnostics (medical/biological)
  Industry 2 T-SPOT® technology
Persons Person Wrighton-Smith, Peter (Oxford Immunotec 200508 CEO)
  Person 2 Altieri, Richard M. (Rick) (Oxford Immunotec 201311 CFO)
Region Region Abingdon, Oxfordshire
  Country United Kingdom (GB)
  Street 115D Innovation Drive
Milton Park
  City OX14 4RZ Abingdon, Oxfordshire
  Tel +44-1235-442-780
    Address record changed: 2018-07-24
Basic data Employees n. a.
  Currency USD
  Annual sales 62,800,000 (revenue, total (2015) 2015-12-31)
  Profit -24,500,000 (2015-12-31)
  Cash 83,700,000 (2015-12-31)
    * Document for �About Section�: Oxford Immunotec Global plc. (8/30/17). "Press Release: Oxford Immunotec to Present at the Baird 2017 Global Healthcare Conference". Oxford & Marlborough, MA.
Record changed: 2018-10-31


Picture [iito] Männer Ballett 650x80px

More documents for Oxford Immunotec (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture Kentro Design Corporate and Web Design Berlin 650x65px

» top